

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 May 2011 (12.05.2011)

(10) International Publication Number
WO 2011/054620 A1

PCT

(51) International Patent Classification:
A61K 31/445 (2006.01) *A61K 35/00* (2006.01)
A61K 31/5377 (2006.01)

(21) International Application Number:
PCT/EP2010/065149

(22) International Filing Date:
11 October 2010 (11.10.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/250,852 12 October 2009 (12.10.2009) US

(71) Applicant (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BELVIN, Marcia** [US/US]; 1 DNA Way, MS49, South San Francisco, CA 94080 (US). **CHAN, Iris, T.** [US/US]; 1 DNA Way, MS49, South San Francisco, CA 94080 (US). **FRIEDMAN, Lori** [US/US]; 1 DNA Way, MS49, South San Francisco, CA 94080 (US). **HOEFLICH, Klaus, P.** [CA/US]; 1 DNA Way, MS49, South San Francisco, CA 94080 (US). **PRESCOTT, John** [US/US]; 1 DNA Way, MS49, South San Francisco, CA 94080 (US). **WALLIN, Jeffrey** [US/US]; 1 DNA Way, MS49, South San Francisco, CA 94080 (US).

(74) Agent: **SAUER, Frank**; F. Hoffmann-La Roche AG, Grenzacherstrasse 124, CH-4070 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: COMBINATIONS OF A PI3K INHIBITOR AND A MEK INHIBITOR

(57) Abstract: The invention relates to methods of treating a patient with locally advanced or metastatic solid tumors with a combination of an inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase or PI3K) and an inhibitor of mitogen activated protein kinase kinase (MEK) described herein.



WO 2011/054620 A1

COMBINATIONS OF A PI3K INHIBITOR AND A MEK INHIBITOR

The invention relates to methods of treating a patient with locally advanced or metastatic solid tumors with a combination of an inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase or PI3K) and an inhibitor of mitogen activated protein kinase kinase (MEK) described herein.

The mitogen-activated protein kinase (MAPK) signaling cascade transduces multiple proliferative and differentiating signals within tumor cells. Four MAPK pathways have been identified: extracellular signal-regulated kinase (ERK), c-Jun NH₂-terminal kinase (JNK), p38 kinase, and ERK5 (Johnson and Lapadat, *Science* 2002;298(5600):1911-2). Different extracellular signals can stimulate one or more of these pathways.

The RAS/RAF/MAPK/ERK pathway plays a major role in mediating cell growth and differentiation in response to numerous extracellular signals. Ras-GTP activates Raf kinase, which in turn activates the MEK/ERK pathway and drives cellular proliferation (Downward, *Nat Rev Cancer*. 2003;3(1):11-22). To regulate cellular proliferation, activated ERKs translocate to the nucleus and regulate gene expression through the activation of several key transcription factors. Abnormal regulation of the RAS/RAF/MEK/ERK pathway contributes to uncontrolled proliferation, invasion, metastasis, angiogenesis, and diminished apoptosis.

Inhibitors of MEK would be expected to be most efficacious in tumors that are highly dependent on proliferative signals from the RAS/RAF/MEK/ERK signaling pathway. Mutation and/or over-expression of EGFR as well as mutations in the KRAS, NRAS, and BRAF oncogenes activate this pathway in many cancers. RAS is mutated in approximately 30% of all solid tumors (Wellcome Trust Sanger Institute, COSMIC database). Oncogenic KRAS mutations are found with high incidence in pancreatic adenocarcinoma (90%), colorectal adenocarcinoma (30%–50%) and non-small cell lung cancer (30%) (Johnson et al., *Nature* 2001;410:1111–1116). Activating somatic mutations in the B-RAF oncogene, (e.g., B-RAF^{V600E}) have been identified in a number of malignancies, with the highest incidence in malignant melanoma (60%–80%), papillary thyroid cancer (35%–70%), colorectal cancer (about 10%), and endometrial cancer (10%–20%). Cancer cells transformed by B-RAF^{V600E} are exceptionally sensitive to MEK inhibition. There-

fore, MEK inhibitors may have particular clinical utility in melanoma and other tumors harboring the B-RAF^{V600E} mutation (Solit, *Nature* 2006; 441:424–30).

The phosphoinositide 3-kinase (PI3K) signaling pathway is a major downstream effector of receptor tyrosine kinases that stimulate cell proliferation, promote survival, and inhibit apoptosis, such as human epidermal growth factor-2 (HER2), epidermal growth factor receptor (EGFR), and insulin-like growth factor-1 receptor. Abnormal regulation of this central signaling pathway has been identified in a large number of cancer types, occurring through a variety of mechanisms. The pathway is constitutively activated by the loss of the tumor suppressor phosphatase and tensin homolog (PTEN), a phosphatase that counteracts the kinase activity of PI3K, in many tumor types (Li et al., *Science* 1997;275:1943–7; Steck et al., *Nat Genet* 1997;15:356–62). AKT, a downstream target for PI3K, is overexpressed in some tumor types (Staal, *Proc Nat Acad Sci USA* 1987;84(14):5034–7; Cheng et al., *Proc Nat Acad Sci USA* 1992;89(19):9267–71; Bellacosa et al., *Int J Cancer* 1995;64(4):280–5) and has been shown to be transforming (Aoki et al., *Proc Nat Acad Sci USA* 1998;95(25):14950–5). Activating mutations of PI3K- α , which belongs to the class IA PI3K family, have been observed in a number of different tumor types (Bachman et al., *Cancer Biol Ther* 2004;3:772–5; Samuels et al., *Science* 2004;304:554).

These activating mutations have been shown to promote growth and invasion in cancer cells, effects that are abrogated by PI3K inhibitors. Taken together, these data provide a strong rationale for developing inhibitors of PI3K pathway signaling as a therapeutic strategy for human cancer.

Many cancers (e.g., melanoma, colorectal, pancreatic, ovarian, NSCLC, and thyroid cancers) have a high and overlapping frequency of oncogenic mutations that activate both RAS and PI3K pathways. Furthermore, in tumor cells, inhibition of one activated pathway can result in activation of the other; therefore, inhibition of both RAS and PI3K pathways represents a new anti-cancer strategy. Thus, combined MEK and PI3K inhibition is an exciting approach to treat cancers.

The invention relates to methods of treating a patient with locally advanced or metastatic solid tumors with 4-(2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine (**I**), also known as GDC-0941, or (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one (**II**) (US 2008/0076768; WO 2006/046031), both of which inhibit PI3K, in combi-

nation with an inhibitor of MEK described in herein. The invention further relates to combination therapy of **I** or **II** and a MEK inhibitor wherein the inhibitor is [3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-((S)-3-hydroxy-3-piperidin-2-yl-azetidin-1-yl)-methanone also known as GDC-0973/XL-518 (**III**).

- 5 The invention further relates to dosages of **I** or **II** and **III** which can be used in combination therapy and dosing regimes useful for practicing combination therapy with **I** or **II** and **III**.

Figure 1 shows in vitro synergy observed with GDC-0941 and GDC-0973. The combination index (CI) of GDC-0941 and GDC-0973 in a panel of melanoma and NSCLC cell lines was plotted. Each dot represents a single cell line. According to the Chou and Talalay (1984) (*Adv.*

- 10 *Enz. Regul.* 1984 22:27-55) method, a combination index <0.3 indicates strong synergy and a combination index <0.7 indicates synergy.

Figure 2 shows combination of GDC-0973 and GDC-0941 in the NCI-H2122 (NSCLC, K-Ras^{G12C}) mutant Xenograft model. NCI-H2122 cells (10×10^6 in Hanks Balance Salt Solution (HBSS) + Matrigel) were inoculated into nude mice (nu/nu) and tumors were allowed to

- 15 establish to an average volume of $\sim 240 \text{ mm}^3$. Treatment was then begun dosing Vehicle (open circles, small dashed lines, n=10), GDC-0941 (50 mg/kg, QD, PO; half-filled boxes, dashed lines, n=5), GDC-973 (5 mg/kg, QD, PO; filled triangles, large dashed lines, n=5), or the combination of GDC-0941 and GDC-0973 (filled diamonds, solid lines, n=5). Caliper measurements of animals' tumors and animal weights were taken every 3-4 days throughout the study and
- 20 tumor volumes were calculated ($TV = [L \times (W^2)]/2$) and plotted \pm SEM. Percent tumor growth inhibition was calculated by calculating the area under the curve (AUC) of each treatment group relative to vehicle control. Student's t-tests were performed on day 21 data to determine significance by p-value.

Figure 3 shows combination of GDC-0973 and GDC-0941 in the A2058 (Melanoma, B-Raf^{V600E},

- 25 PTEN^{null}) mutant Xenograft model. A2058 cells (10×10^6 in Hanks Balance Salt Solution (HBSS) + Matrigel) were inoculated into nude mice (nu/nu) and tumors were allowed to establish to an average volume of $\sim 190 \text{ mm}^3$. (A) Treatment was then begun dosing Vehicle (open circles, small dashed lines, n=7), GDC-0941 (30 mg/kg, QD, PO; half-filled boxes, dashed lines, n=7), GDC-973 (6 mg/kg, QD, PO; filled triangles, large dashed lines, n=7), or the combination of GDC-0941 and GDC-0973 (filled diamonds, solid lines, n=7). (B) Treatment was then
- 30 begun dosing Vehicle (open circles, small dashed lines, n=7), GDC-0941 (100 mg/kg, QD, PO;

half-filled boxes, dashed lines, n=7), GDC-0973 (10 mg/kg, QD, PO; filled triangles, large dashed lines, n=7), or the combination of GDC-0941 and GDC-0973 (filled diamonds, solid lines, n=7). Caliper measurements of animals' tumors and animal weights were taken every 3-4 days throughout the study and tumor volumes were calculated ($TV = [L \times (W^2)]/2$) and plotted +/- SEM. Percent tumor growth inhibition was calculated by calculating the area under the curve (AUC) of each treatment group relative to vehicle control. Student's t-tests were performed on day 21 data to determine significance by p-value.

Figure 4 shows combination of GDC-0941 and GDC-0973 in (A) the FaDu (hypopharyngeal squamous cell carcinoma) Xenograft model. (A) Treatment was then begun dosing Vehicle (open circles), GDC-0941 (100 mg/kg, QD, PO; filled triangles), GDC-973 (5 mg/kg, QD, PO; filled squares), or the combination of GDC-0941 and GDC-0973 (filled diamonds, solid lines, n=7). (B) the SKOV-4 (ovarian) Xenograph model. Treatment was then begun dosing Vehicle (open circles), GDC-0941 (100 mg/kg, QD, PO; filled triangles), GDC-0973 (10 mg/kg, QD, PO; filled squares), or the combination of GDC-0941 and GDC-0973 (filled diamonds). Caliper measurements of animals' tumors and animal weights were taken every 3-4 days throughout the study and tumor volumes were calculated ($TV = [L \times (W^2)]/2$) and plotted +/- SEM. Percent tumor growth inhibition was calculated by calculating the area under the curve (AUC) of each treatment group relative to vehicle control. Student's t-tests were performed on day 21 data to determine significance by p-value.

Figure 5 shows combination of GDC-0941 and GDC-0973 in (A) the MOLM-16 (acute myeloid leukemia) Xenograft model. ##A2058 cells (10×10^6 in Hanks Balance Salt Solution (HBSS) + Matrigel) were inoculated into nude mice (nu/nu) and tumors were allowed to establish to an average volume of $\sim 190 \text{ mm}^3$. (A) Treatment was then begun dosing Vehicle (open circles), GDC-0941 (100 mg/kg, QD, PO; filled triangles), GDC-973 (10 mg/kg, QD, PO; filled squares), or the combination of GDC-0941 and GDC-0973 (filled diamonds, solid lines, n=7). (B) the MX-1 (triple negative breast) Xenograph model. Treatment was then begun dosing Vehicle (open circles), GDC-0941 (100 mg/kg, QD, PO; filled triangles), GDC-0973 (5 mg/kg, QD, PO; filled squares), or the combination of GDC-0941 and GDC-0973 (filled diamonds). Caliper measurements of animals' tumors and animal weights were taken every 3-4 days throughout the study and tumor volumes were calculated ($TV = [L \times (W^2)]/2$) and plotted +/- SEM. Percent tumor growth inhibition was calculated by calculating the area under the curve (AUC) of each treatment group relative to vehicle control. Student's t-tests were performed on day 21 data to

determine significance by p-value.

Figures 6a and 6b show dosing schema for GDC-0973 and GDC-0941 combination.

Reference will now be made in detail to certain embodiments of the invention, examples of which are illustrated in the accompanying structures and formulas. While the invention will be described in conjunction with the enumerated embodiments, it will be understood that they are not intended to limit the invention to those embodiments. On the contrary, the invention is intended to cover all alternatives, modifications, and equivalents which may be included within the scope of the present invention. One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. The present invention is in no way limited to the methods and materials described. In the event that one or more of the incorporated literature, patents, and similar materials differs from or contradicts this application, including but not limited to defined terms, term usage, described techniques, or the like, this application controls.

The words "comprise", "comprising", "include", "including" and "includes" when used in this specification and claims are intended to specify the presence of stated features, integers, components, or steps, but they do not preclude the presence or addition of one or more other features, integers, components, steps, or groups thereof.

The terms "treat" and "treating" refer to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological change or disorder, such as the growth, development or spread of cancer. For purposes of this invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. "Treat" and "treating" can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the condition or disorder as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented.

The term "locally advanced or metastatic solid tumors" includes melanoma, non-small cell lung cancer ("NSCLC"), colorectal cancer, pancreatic cancer, breast cancer and ovarian cancer.

A "metabolite" is a product produced through metabolism in the body of a specified compound

or salt thereof. Metabolites of a compound may be identified using routine techniques known in the art and their activities determined using tests such as those described herein. Such products may result e.g. from the oxidation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, enzymatic cleavage, and the like, of the administered compound. Accordingly, the invention includes metabolites of compounds of the invention, including compounds produced by a process comprising contacting a compound of this invention with a mammal for a period of time sufficient to yield a metabolic product thereof.

The phrase "pharmaceutically acceptable salt" as used herein, refers to pharmaceutically acceptable organic or inorganic salts of a compound of the invention. Exemplary salts include, but are not limited, to sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate "mesylate", ethanesulfonate, benzenesulfonate, *p*-toluenesulfonate, and pamoate (i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)) salts. A pharmaceutically acceptable salt may involve the inclusion of another molecule such as an acetate ion, a succinate ion or other counter ion. The counter ion may be any organic or inorganic moiety that stabilizes the charge on the parent compound. Furthermore, a pharmaceutically acceptable salt may have more than one charged atom in its structure. Instances where multiple charged atoms are part of the pharmaceutically acceptable salt can have multiple counter ions. Hence, a pharmaceutically acceptable salt can have one or more charged atoms and/or one or more counter ion.

If the compound of the invention is a base, the desired pharmaceutically acceptable salt may be prepared by any suitable method available in the art, e.g., treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, methanesulfonic acid, phosphoric acid and the like, or with an organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha hydroxy acid, such as citric acid or tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an aromatic acid, such as benzoic acid or cinnamic acid, a sulfonic acid, such as *p*-toluenesulfonic acid or ethanesulfonic acid, or the like. Acids which are generally considered suitable for the formation of pharmaceutically useful or acceptable salts from basic pharmaceutical compounds are discussed, e.g., by Stahl et al, Camille (eds.) Handbook of Pharmaceutical Salts. Pro-

perties, Selection and Use. (2002) Zurich: Wiley-VCH; Berge et al, Journal of Pharmaceutical Sciences (1977) 66(1) 1 19; Gould, International J. of Pharmaceutics (1986) 33 201 217; Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York; Remington's Pharmaceutical Sciences, 18th ed., (1995) Mack Publishing Co., Easton PA; and in The Orange Book (Food & Drug Administration, Washington, D.C. on their website).

If the compound of the invention is an acid, the desired pharmaceutically acceptable salt may be prepared by any suitable method, e.g., treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide or alkaline earth metal hydroxide, or the like. Illustrative examples of suitable salts include, but are not limited to, organic salts derived from amino acids, such as glycine and arginine, ammonia, primary, secondary, and tertiary amines, and cyclic amines, such as piperidine, morpholine and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium.

The phrase "pharmaceutically acceptable" indicates that the substance or composition must be compatible chemically and/or toxicologically, with the other ingredients comprising a formulation, and/or the mammal being treated therewith.

A "solvate" refers to a physical association or complex of one or more solvent molecules and a compound of the invention. The compounds of the invention may exist in unsolvated as well as solvated forms. Examples of solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine. The term "hydrate" refers to the complex where the solvent molecule is water. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, e.g. when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. Preparation of solvates is generally known, e.g., Caira et al, J. Pharmaceutical Sci., 93(3), 601 611 (2004). Similar preparations of solvates, hemisolvate, hydrates and the like are described by van Tonder et al, AAPS PharmSciTech., 5(1), article 12 (2004); and Bingham et al, Chem. Commun., 603 604 (2001). A typical, non-limiting, process involves dissolving the inventive compound in desired amounts of the desired solvent (organic or water or mixtures thereof) at a higher than ambient temperature, and cooling the solution at a rate sufficient to form crystals which are then isolated by standard methods. Analytical techniques such as, e.g. I.R. spectroscopy, show the presence of the solvent (or water) in the crystals as a solvate (or hydrate).

Despite recent advances in human tumor profiling and small and large molecule drug design leading to the discovery of targeted therapeutics that have altered the history of the diseases for which they were initially developed, the overall success rate of targeted agents in oncology is, however, still rather low, which may be partially explained by the heterogeneity of many cancers as well as the complex pathways in which the targets act, which involve multiple redundant pathways and cross-talk among many molecular pathways.


One way to approach this problem is to treat tumors with a combination of targeted agents, such as targeting both the MAPK/ERK pathway and the PI3K/AKT/mTOR pathway. These are pathways that independently and together drive proliferation in many tumors and are usually activated in tumors by a number of genomic events. This approach has a dual benefit: it has the potential to increase the initial tumor response rate in tumors driven by multiple oncogenic events, as well as to decrease the rates of acquired resistance that could occur with either agent alone. This is due to the inhibition of the activating compensatory pathways, which would then prolong the activity of the combination over the activity seen by either agent alone.

PI3K–AKT pathway activation has been implicated in several types of cancer (Ward et al., *Chem Biol* 2003;10:207–13; Cantley, In: The Harvey Lectures, Series 100, 2004–2005. Hoboken: John Wiley and Sons Inc., 2006:103–22). Activating and transforming mutations in the p110 α subunit of PI3K are commonly found in tumors (Bachman et al., *Cancer Biol Ther* 2004; 3:772–5; Samuels et al., *Science* 2004;304:554; Karakas et al., *Br J Cancer* 2006; 94:455–9). In addition, the pathway is activated in numerous types of cancer by receptor tyrosine kinase signaling, RAS mutations, or the loss of the phosphatase PTEN (Cantley, *Science* 2002;296:1655–7).

Targeting either of these pathways individually can attenuate signaling and has been shown to be efficacious in some animal models (Folkes et al., *J Med Chem* 2008;51:5522–32; Hoeflich et al., *Clin Cancer Res*, 2009 15(14):4649-4664)). However, in many tumors, cell proliferation and survival are driven through multiple effector pathways, such as in tumors with concurrent activation of the RAS and PI3K pathways, as is seen frequently in melanoma, lung cancer, and colorectal cancer. In these cases, targeting both of these pathways non-clinically has been shown to be significantly more efficacious than targeting either pathway alone. For example, MEK and PI3K inhibitors have demonstrated improved combination efficacy in KRAS mutant mouse models of lung cancer or breast cancer compared with the single agents (Engelman et al., *Nat Med* 2008;14:1351–6; Hoeflich et al., *Clin Cancer Res*, 2009 15(14):4649-4664)). Nonclinical data demonstrating in vitro and in vivo combination efficacy of a MEK inhibitor and a PI3K


inhibitor are described herein and in US2009/0098135, the content of which is incorporated herein by reference. Because non-clinical models suggests that inhibition of both the PI3K and MEK pathways results in improved efficacy particularly in RAF and RAS mutant genotypes. Hence, a MEK (such as GDC-0973) and PI3K (such as GDC-0941) inhibitor combination is particularly beneficial in RAS/RAF mutant patients with locally advanced or metastatic solid tumors.

The invention relates to methods of treating a patient with locally advanced or metastatic solid tumors with 4-(2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine (**I**), also known as GDC-0941, or (*S*)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one (**II**) (US 2008/0076768; WO 2006/046031), both of which inhibit PI3K, in combination with an inhibitor of MEK described in US2009/0156576, the content of which is incorporated herein by reference in its entirety.



GDC-0941 or **II** may be prepared following the methods described in US 2008/0076768, US2008/0207609, US2008/0207611 and US2009/0131429 (the content of which are incorporated herein by reference in their entirety).

The MEK inhibitor useful in combination with GDC-0941, an inhibitor of PI3K, to treat patients with locally advanced or metastatic solid tumors, as described in the methods herein, including GDC-0973/XL-518 (**III**), is listed below in Table 1. MEK inhibitors of Table 1 including GDC-0973/XL-518 may be prepared following the methods described in US2009/0156576.



(III)

In one embodiment of the invention there is provided a method of treating a patient with locally advanced or metastatic solid tumors with 4-(2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine, also known as GDC-0941, an inhibitor of PI3K, in combination with an inhibitor of MEK described herein.

In another embodiment of the present invention there is provided a method of treating a patient with locally advanced or metastatic solid tumors comprising administering to said patient concurrently GDC-0941 in combination with a MEK inhibitor selected from Table 1, including GDC-0973/XL-518.

10 In one embodiment of the invention there is provided a method of treating a patient with locally advanced or metastatic solid tumors with (*S*)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one (**II**), an inhibitor of PI3K, in combination with an inhibitor of MEK described in herein.

15 In another embodiment of the present invention there is provided a method of treating a patient with locally advanced or metastatic solid tumors comprising administering to said patient concurrently **II** in combination with a MEK inhibitor selected from Table 1, including GDC-0973/XL-518.

20 In another embodiment of the present invention relates to a method of treating a patient with locally advanced or metastatic solid tumors comprising administering to said patient concurrently GDC-0941 (**I**) and GDC-0973/XL-518 (**III**).

In another embodiment the present invention relates to a method of treating a patient with locally advanced or metastatic solid tumors comprising administering to said patient concurrently **II** and GDC-0973/XL-518 (**III**).

25 In another embodiment of the present invention there is provided a method of treating a patient with locally advanced or metastatic solid tumors comprising administering to said patient con-

currently GDC-0941 (I) in combination with a MEK inhibitor selected from Table 1, including GDC-0973/XL-518 (III), wherein said patient is on a 28-day cycle in which said patient is administered with both GDC-0941 and a MEK inhibitor selected from Table 1, including GDC-0973/XL-518 for 21 consecutive days, and no GDC-0941 or a MEK inhibitor selected from
5 Table 1, including GDC-0973/XL-518 for the next 7 consecutive days.

In another embodiment of the present invention there is provided a method of treating a patient with locally advanced or metastatic solid tumors comprising administering to said patient concurrently GDC-0941 in combination with a MEK inhibitor selected from Table 1, including GDC-0973/XL-518, wherein said patient is on a 28-day cycle in which said patient is admini-
10 stered with both GDC-0941 and a MEK inhibitor selected from Table 1, including GDC-0973/XL-518 for 14 consecutive days, and no GDC-0941 or a MEK inhibitor selected from Table 1, including GDC-0973/XL-518 for the next 14 consecutive days.

In another embodiment of the present invention there is provided a method of treating a patient with locally advanced or metastatic solid tumors comprising administering to said patient con-
15 currently GDC-0941 in combination with a MEK inhibitor selected from Table 1, including GDC-0973/XL-518, wherein said patient is on a 28-day cycle in which said patient is administered with both GDC-0941 and a MEK inhibitor selected from Table 1, including GDC-0973/XL-518 for 21 consecutive days, and no GDC-0941 or a MEK inhibitor selected from Table 1, including GDC-0973/XL-518 for the next 7 consecutive days.

20 In another embodiment of the present invention there is provided a method of treating a patient with locally advanced or metastatic solid tumors comprising administering to said patient concurrently GDC-0941 and GDC-0973/XL-518, wherein said patient is on a 28-day cycle in which said patient is administered with both GDC-0941 and GDC-0973/XL-518 for 14 consecutive days, and no GDC-0941 or GDC-0973/XL-518 for the next 14 consecutive days.

25 In another embodiment of the present invention there is provided a method of treating a patient with locally advanced or metastatic solid tumors comprising administering to said patient concurrently II and GDC-0973/XL-518, wherein said patient is on a 28-day cycle in which said patient is administered with both II and GDC-0973/XL-518 for 14 consecutive days, and no II or GDC-0973/XL-518 for the next 14 consecutive days.

30 In another embodiment of the present invention there is provided a method of treating a patient

with locally advanced or metastatic solid tumors comprising administering to said patient concurrently 80mg, 100mg, 130mg or 180mg of GDC-0941 or II in combination with 20mg, 40mg or 60mg of a MEK inhibitor selected from Table 1, including GDC-0973/XL-518.

5 In another embodiment of the present invention there is provided a method of treating a patient with locally advanced or metastatic solid tumors comprising administering to said patient concurrently 80mg, 100mg, 130mg or 180mg of GDC-0941 or II and 20mg, 40mg or 60mg of GDC-0973/XL-518.

10 In another embodiment of the present invention there is provided a method of treating a patient with locally advanced or metastatic solid tumors comprising administering to said patient concurrently 80mg, 100mg, 130mg or 180mg of GDC-0941 or II in combination with 20mg, 40mg or 60mg of a MEK inhibitor selected from Table 1, including GDC-0973/XL-518, wherein said patient is on a 28-day cycle in which said patient is administered with both GDC-0941 or II and MEK inhibitor selected from Table 1, including GDC-0973/XL-518 for 21 consecutive days, and no GDC-0941 or II or a MEK inhibitor selected from Table 1, including GDC-0973/XL-518 for
15 the next 7 consecutive days.

In another embodiment of the present invention there is provided a method of treating a patient with locally advanced or metastatic solid tumors comprising administering to said patient concurrently 80mg, 100mg, 130mg or 180mg of GDC-0941 or II in combination with 20mg, 40mg or 60mg of a MEK inhibitor selected from Table 1, including GDC-0973/XL-518, wherein said
20 patient is on a 28-day cycle in which said patient is administered with both GDC-0941 or II and a MEK inhibitor selected from Table 1, including GDC-0973/XL-518 for 14 consecutive days, and no GDC-0941 or II or a MEK inhibitor selected from Table 1, including GDC-0973/XL-518 for the next 14 consecutive days.

In another embodiment of the present invention there is provided a method of treating a patient
25 with locally advanced or metastatic solid tumors comprising administering to said patient concurrently 80mg, 100mg, 130mg or 180mg of GDC-0941 or II and 20mg, 40mg or 60mg of GDC-0973/XL-518, wherein said patient is on a 28-day cycle in which said patient is administered with both GDC-0941 or II and GDC-0973/XL-518 for 21 consecutive days, and no GDC-0941 or II or GDC-0973/XL-518 for the next 7 consecutive days.

30 In another embodiment of the present invention there is provided a method of treating a patient

with locally advanced or metastatic solid tumors comprising administering to said patient concurrently 80mg, 100mg, 130mg or 180mg of GDC-0941 or II and 20mg, 40mg or 60mg of GDC-0973/XL-518, wherein said patient is on a 28-day cycle in which said patient is administered with both GDC-0941 or II and GDC-0973/XL-518 for 14 consecutive days, and no GDC-0941 or II or GDC-0973/XL-518 for the next 14 consecutive days.

In another embodiment of the present invention there is provided methods of treating a patient with RAS/RAF mutant locally advanced or metastatic solid tumors with 4-(2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine, also known as GDC-0941, an inhibitor of PI3K, in combination with an inhibitor of MEK described in herein.

In another embodiment of the present invention there is provided methods of treating a patient with RAS/RAF mutant locally advanced or metastatic solid tumors with (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one (II), an inhibitor of PI3K, in combination with an inhibitor of MEK described in herein.

In another embodiment of the present invention there is provided a method of treating a patient with RAS/RAF mutant locally advanced or metastatic solid tumors comprising administering to said patient concurrently GDC-0941 or II in combination with a MEK inhibitor selected from Table 1, including GDC-0973/XL-518.

In another embodiment of the present invention there is provided a method of treating a patient with RAS/RAF mutant locally advanced or metastatic solid tumors comprising administering to said patient concurrently GDC-0941 or II and GDC-0973/XL-518.

In another embodiment of the present invention there is provided a method for the treatment of a patient with a locally advanced or metastatic solid tumor comprising administering a therapeutic combination, as a combined formulation or by alternation, to a mammal wherein the therapeutic combination comprises a therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt of I or II, and a therapeutically effective amount of a compound of formula III, or a pharmaceutically acceptable salt of III, wherein said locally advanced or metastatic solid tumors are subject to abnormal regulation of the RAS/RAF/MEK/ERK pathway.

In another embodiment of the present invention there is provided a method for the treatment of a patient with a locally advanced or metastatic solid tumor comprising administering a therapeutic combination, as a combined formulation or by alternation, to a mammal wherein the therapeutic combination comprises a therapeutically effective amount of a compound of formula **I** or **II**, or a pharmaceutically acceptable salt of **I** or **II**, and a therapeutically effective amount of a compound of formula **III**, or a pharmaceutically acceptable salt of **III**, wherein said locally advanced or metastatic solid tumors express mutations of the RAS or RAF genes.

In another embodiment of the present invention there is provided a method for the treatment of a patient with a locally advanced or metastatic solid tumor comprising administering a therapeutic combination, as a combined formulation or by alternation, to a mammal wherein the therapeutic combination comprises a therapeutically effective amount of a compound of formula **I** or **II**, or a pharmaceutically acceptable salt of **I** or **II**, and a therapeutically effective amount of a compound of formula **III**, or a pharmaceutically acceptable salt of **III**, wherein said locally advanced or metastatic solid tumors are subject to abnormal regulation of the PI3K signaling pathway.

In another embodiment of the present invention there is provided a method for the treatment of a patient with a locally advanced or metastatic solid tumor comprising administering a therapeutic combination, as a combined formulation or by alternation, to a mammal wherein the therapeutic combination comprises a therapeutically effective amount of a compound of formula **I** or **II**, or a pharmaceutically acceptable salt of **I** or **II**, and a therapeutically effective amount of a compound of formula **III**, or a pharmaceutically acceptable salt of **III**, wherein said locally advanced or metastatic solid tumors over-express PI3K or Akt, e.g. wherein said locally advanced or metastatic solid tumors express mutations of the PI3K gene or wherein said locally advanced or metastatic solid tumors exhibit loss of the tumor suppressor phosphatase and tensin homolog (PTEN).

In another embodiment of the present invention there is provided a method for the treatment of a patient with a locally advanced or metastatic solid tumor comprising administering a therapeutic combination, as a combined formulation or by alternation, to a mammal wherein the therapeutic combination comprises a therapeutically effective amount of a compound of formula **I** or **II**, or a pharmaceutically acceptable salt of **I** or **II**, and a therapeutically effective amount of a compound of formula **III**, or a pharmaceutically acceptable salt of **III**, wherein said locally advanced or metastatic solid tumors are selected from the group consisting of pancreatic adenocarcinoma, colorectal adenocarcinoma, non-small cell lung cancer, malignant melanoma, papillary thyroid cancer, breast, ovarian and endometrial cancer.

In another embodiment of the present invention there is provided a method of treating a patient with RAS/RAF mutant locally advanced or metastatic solid tumors comprising administering to said patient concurrently GDC-0941 or II in combination with a MEK inhibitor selected from Table 1, including GDC-0973/XL-518, wherein said patient is on a 28-day cycle in which said patient is administered with both GDC-0941 or II and a MEK inhibitor selected from Table 1, including GDC-0973/XL-518 for 21 consecutive days, and no GDC-0941 or II or a MEK inhibitor selected from Table 1, including GDC-0973/XL-518 for the next 7 consecutive days.

In another embodiment of the present invention there is provided a method of treating a patient with RAS/RAF mutant locally advanced or metastatic solid tumors comprising administering to said patient concurrently GDC-0941 or II in combination with a MEK inhibitor selected from Table 1, including GDC-0973/XL-518, wherein said patient is on a 28-day cycle in which said patient is administered with both GDC-0941 or II and a MEK inhibitor selected from Table 1, including GDC-0973/XL-518 for 14 consecutive days, and no GDC-0941 or II or a MEK inhibitor selected from Table 1, including GDC-0973/XL-518 for the next 14 consecutive days.

In another embodiment of the present invention there is provided a method of treating a patient with RAS/RAF mutant locally advanced or metastatic solid tumors comprising administering to said patient concurrently GDC-0941 or II in combination with a MEK inhibitor selected from Table 1, including GDC-0973/XL-518, wherein said patient is on a 28-day cycle in which said patient is administered with both GDC-0941 or II and a MEK inhibitor selected from Table 1, including GDC-0973/XL-518 for 21 consecutive days, and no GDC-0941 or II or a MEK inhibitor selected from Table 1, including GDC-0973/XL-518 for the next 7 consecutive days.

In another embodiment of the present invention there is provided a method of treating a patient with RAS/RAF mutant locally advanced or metastatic solid tumors comprising administering to said patient concurrently GDC-0941 or II and GDC-0973/XL-518, wherein said patient is on a 28-day cycle in which said patient is administered with both GDC-0941 or II and GDC-0973/XL-518 for 14 consecutive days, and no GDC-0941 or II or GDC-0973/XL-518 for the next 14 consecutive days.

In another embodiment of the present invention there is provided a method of treating a patient with RAS/RAF mutant locally advanced or metastatic solid tumors comprising administering to said patient concurrently 80mg, 100mg, 130mg or 180mg of GDC-0941 or II in combination with 20mg, 40mg or 60mg of a MEK inhibitor selected from Table 1, including GDC-0973/XL-

518.

In another embodiment of the present invention there is provided a method of treating a patient with RAS/RAF mutant locally advanced or metastatic solid tumors comprising administering to said patient concurrently 80mg, 100mg, 130mg or 180mg of GDC-0941 or II and 20mg, 40mg or 60mg of GDC-0973/XL-518.

In another embodiment of the present invention there is provided a method of treating a patient with RAS/RAF mutant locally advanced or metastatic solid tumors comprising administering to said patient concurrently 80mg, 100mg, 130mg or 180mg of GDC-0941 or II in combination with 20mg, 40mg or 60mg of a MEK inhibitor selected from Table 1, including GDC-0973/XL-518, wherein said patient is on a 28-day cycle in which said patient is administered with both GDC-0941 or II and MEK inhibitor selected from Table 1, including GDC-0973/XL-518 for 21 consecutive days, and no GDC-0941 or II or a MEK inhibitor selected from Table 1, including GDC-0973/XL-518 for the next 7 consecutive days.

In another aspect, the invention relates to a method of treating a patient with RAS/RAF mutant locally advanced or metastatic solid tumors comprising administering to said patient concurrently 80mg, 100mg, 130mg or 180mg of GDC-0941 or II in combination with 20mg, 40mg or 60mg of a MEK inhibitor selected from Table 1, including GDC-0973/XL-518, wherein said patient is on a 28-day cycle in which said patient is administered with both GDC-0941 or II and a MEK inhibitor selected from Table 1, including GDC-0973/XL-518 for 14 consecutive days, and no GDC-0941 or II or a MEK inhibitor selected from Table 1, including GDC-0973/XL-518 for the next 14 consecutive days.

In another embodiment of the present invention there is provided a method of treating a patient with RAS/RAF mutant locally advanced or metastatic solid tumors comprising administering to said patient concurrently 80mg, 100mg, 130mg or 180mg of GDC-0941 or II and 20mg, 40mg or 60mg of GDC-0973/XL-518, wherein said patient is on a 28-day cycle in which said patient is administered with both GDC-0941 or II and GDC-0973/XL-518 for 21 consecutive days, and no GDC-0941 or II or GDC-0973/XL-518 for the next 7 consecutive days.

In another embodiment of the present invention there is provided a method of treating a patient with RAS/RAF mutant locally advanced or metastatic solid tumors comprising administering to said patient concurrently 80mg, 100mg, 130mg or 180mg of GDC-0941 or II and 20mg, 40mg or




60mg of GDC-0973/XL-518, wherein said patient is on a 28-day cycle in which said patient is administered with both GDC-0941 or II and GDC-0973/XL-518 for 14 consecutive days, and no GDC-0941 or II or GDC-0973/XL-518 for the next 14 consecutive days.






In another aspect, methods of treatments of the invention include those comprising administering
 5 GDC-0941 or II and a MEK inhibitor selected from Table 1, including GDC-0973/XL-518 in the form of various pharmaceutically acceptable salts and/or pharmaceutical compositions.






The PI3K inhibitor GDC-0941 (I), II and MEK inhibitors described herein such as those in Table 1, including GDC-0973/XL-518 (II) include all stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof.






10 Pharmaceutical compositions of the invention may further comprise pharmaceutically acceptable carriers, diluents or excipients.






Table 1






Cmpd No.	Structure
1	
2	
3	





Cmpd No.	Structure
4	 <chem>OCC1CN(C1)C(=O)c2cc(F)c(Nc3ccc(I)cc3)c(F)c2</chem>
5	 <chem>OC1CN(C1)C(=O)c2cc(F)c(Nc3ccc(I)cc3)c(F)c2C(F)(F)F</chem>
6	 <chem>C=C[C@H]1CN(C1)C(=O)c2cc(F)c(Nc3ccc(I)cc3)c(F)c2O</chem>
7	 <chem>OCC1CN(C1)C(=O)c2cc(F)c(Nc3ccc(I)cc3)c(F)c2O</chem>
8	 <chem>CC1(C)CN(C1)C(=O)c2cc(F)c(Nc3ccc(I)cc3)c(F)c2</chem>






Cmpd No.	Structure
9	 <chem>CO[C@H]1CN(C(=O)c2cc(F)c(NC3=CC=C(C=C3)F)cc2F)C1O</chem>
10	 <chem>CC=CC1(O)CN(C(=O)c2cc(F)c(NC3=CC=C(C=C3)F)cc2F)C1=O</chem>
11	 <chem>O=[N+]1CN(C(=O)c2cc(F)c(NC3=CC=C(C=C3)F)cc2F)C1</chem>
12	 <chem>OCC1CN(C(=O)c2cc(F)c(NC3=CC=C(C=C3)F)cc2F)C1</chem>
13	 <chem>OCC1(O)CN(C(=O)c2cc(F)c(NC3=CC=C(C=C3)F)cc2F)C1=O</chem>







Cmpd No.	Structure
14	 <chem>NCC1CN(C1)C(=O)c2cc(F)c(Nc3cc(F)cc(I)c3)c(F)c2</chem>
15	 <chem>O=C(NC(=O)N1CCN(C1)C(=O)c2cc(F)c(Nc3cc(F)cc(I)c3)c(F)c2)c4cc(F)c(Nc5cc(F)cc(I)c5)cc4</chem>
16	 <chem>CC(C)(C)OC(=O)NCC1CN(C1)C(=O)c2cc(F)c(Nc3cc(F)cc(I)c3)c(F)c2</chem>
17	 <chem>OCC1CN(C1)C(=O)c2cc(F)c(Nc3cc(F)cc(I)c3)c(F)c2</chem>
18	 <chem>CCN(C)CC1CN(C1)C(=O)c2cc(F)c(Nc3cc(F)cc(I)c3)c(F)c2</chem>






Cmpd No.	Structure
19	
20	
21	
22	
23	






Cmpd No.	Structure
24	 <chem>OCC(O)CC(=O)N[C@@H]1CCN1C(=O)c2cc(F)c(Nc3cc(F)cc(I)c3)c(F)c2</chem>
25	 <chem>COC(=O)N[C@@H]1CCN1C(=O)c2cc(F)c(Nc3cc(F)cc(I)c3)c(F)c2</chem>
26	 <chem>CCCCN[C@@H]1CCN1C(=O)c2cc(F)c(Nc3cc(F)cc(I)c3)c(F)c2</chem>
27	 <chem>N[C@@H]1CCN1C(=O)c2sc(Nc3cc(F)cc(I)c3)c2</chem>
28	 <chem>C1CCN(CC1)[C@H](O)[C@@H]2CCN2C(=O)c3cc(F)c(Nc4cc(F)cc(I)c4)c(F)c3</chem>






Cmpd No.	Structure
29	
30	
31	
32	







Cmpd No.	Structure
33	 <chem>N[C@@H](O)CN(C(=O)c1ccc(Nc2cc(F)cc(I)c2)c3cc(F)c(F)cc3)c4ccccc14</chem>
34	 <chem>N[C@H](O)CN(C(=O)c1ccc(Nc2cc(F)cc(I)c2)c3cc(F)c(F)cc3)c4ccccc14</chem>
35	 <chem>N[C@@H](O)CN(C(=O)c1ccc(Nc2cc(F)cc(I)c2)c3cc(F)c(F)cc3)c4ccccc14</chem>
36	 <chem>CC[C@H](O)CN(C(=O)c1ccc(Nc2cc(F)cc(I)c2)c3cc(F)c(F)cc3)c4ccccc14</chem>
37	 <chem>CC[C@@H](O)CN(C(=O)c1ccc(Nc2cc(F)cc(I)c2)c3cc(F)c(F)cc3)c4ccccc14</chem>

Cmpd No.	Structure
38	
39	
40	
41	
42	
43	






Cmpd No.	Structure
44	
45	
46	
47	
48	






Cmpd No.	Structure
49	
50	
51	
52	
53	






Cmpd No.	Structure
54	
55	
56	
57	
58	





Cmpd No.	Structure
59	
60	
61	
62	
63	
64	






-30-





Cmpd No.	Structure
65	
66	
67	
68	
69	





Cmpd No.	Structure
70	
71	
72	
73	
74	





Cmpd No.	Structure
75	
76	
77	
78	
79	





Cmpd No.	Structure
80	
81	
82	
83	





Cmpd No.	Structure
84	 <chem>CC(=O)NCC1(O)CN1C(=O)Nc2cc(F)c(F)cc2Nc3ccc(I)cc3</chem>
85	 <chem>CC(C)NCC1CN1C(=O)Nc2cc(F)c(F)cc2Nc3ccc(I)cc3</chem>
86	 <chem>CCNCC1(O)CN1C(=O)Nc2cc(F)c(F)cc2Nc3ccc(I)cc3</chem>
87	 <chem>CC(C)NCC1(O)CN1C(=O)Nc2cc(F)c(F)cc2Nc3ccc(I)cc3</chem>
88	 <chem>CC(C)(O)CC1CN1C(=O)Nc2cc(F)c(F)cc2Nc3ccc(I)cc3</chem>





Cmpd No.	Structure
89	
90	
91	
92	





Cmpd No.	Structure
93	
94	
95	
96	





Cmpd No.	Structure
97	 <chem>OCC(O)NC(=O)N1CC(C1)C(=O)c2cc(F)c(Nc3cc(F)c(I)cc3)c(F)c2</chem>
98	 <chem>C1=CN=CN=C1CC1(CN1CC1)C(=O)c2cc(F)c(Nc3cc(F)c(I)cc3)c(F)c2</chem>
99	 <chem>CC(C)(C)CNCC1(CN1CC1)C(=O)c2cc(F)c(Nc3cc(F)c(I)cc3)c(F)c2</chem>
100	 <chem>CCCNCC1(CN1CC1)C(=O)c2cc(F)c(Nc3cc(F)c(I)cc3)c(F)c2</chem>





Cmpd No.	Structure
101	
102	
103	
104	





Cmpd No.	Structure
105	
106	
107	
108	





Cmpd No.	Structure
109	
110	
111	
112	





Cmpd No.	Structure
113	
114	
115	
116	





Cmpd No.	Structure
117	
118	
119	
120	





Cmpd No.	Structure
121	 <chem>COCC(NC1CC2C(=O)N1C3=CC=C(C=C3)C(F)=C(F)C3=CC=C(C=C3)N2C4=CC=C(C=C4)I)C1(O)CC2</chem>
122	 <chem>CCOCCNCC1(O)CC2C(=O)N1C3=CC=C(C=C3)C(F)=C(F)C3=CC=C(C=C3)N2C4=CC=C(C=C4)I</chem>
123	 <chem>CCC(CC)NCC1(O)CC2C(=O)N1C3=CC=C(C=C3)C(F)=C(F)C3=CC=C(C=C3)N2C4=CC=C(C=C4)I</chem>
124	 <chem>CC(C)(C)CCNCC1(O)CC2C(=O)N1C3=CC=C(C=C3)C(F)=C(F)C3=CC=C(C=C3)N2C4=CC=C(C=C4)I</chem>





Cmpd No.	Structure
125	
126	
127	
128	

Cmpd No.	Structure
129	 <chem>O=C(NC1CC1)C(=O)c2cc(F)c(F)cc2Nc3ccc(I)cc3</chem>
130	 <chem>CCN(CC)CCNC1CC1C(=O)Nc2cc(F)c(F)cc2Nc3ccc(I)cc3</chem>
131	 <chem>c1ccncc1CNCCNC1CC1C(=O)Nc2cc(F)c(F)cc2Nc3ccc(I)cc3</chem>
132	 <chem>CSCCNCCNC1CC1C(=O)Nc2cc(F)c(F)cc2Nc3ccc(I)cc3</chem>





Cmpd No.	Structure
133	
134	
135	
136	





Cmpd No.	Structure
137	 <p>Chemical structure of compound 137: A central benzene ring substituted with a 4-iodophenyl group at position 1, a 2-fluoro-4-fluorophenyl group at position 2, and a carbonyl group at position 3. The carbonyl group is connected to a 3-azetidinyl group, which is further connected to a 1-(1H-indol-1-yl)ethyl group.</p>
138	 <p>Chemical structure of compound 138: A central benzene ring substituted with a 4-iodophenyl group at position 1, a 2-fluoro-4-fluorophenyl group at position 2, and a carbonyl group at position 3. The carbonyl group is connected to a 3-azetidinyl group, which is further connected to a 1-(1-(benzyloxy)cyclopentyl)ethyl group.</p>
139	 <p>Chemical structure of compound 139: A central benzene ring substituted with a 4-iodophenyl group at position 1, a 2-fluoro-4-fluorophenyl group at position 2, and a carbonyl group at position 3. The carbonyl group is connected to a 3-azetidinyl group, which is further connected to a 1-(2-amino-2-hydroxyethyl)ethyl group.</p>
140	 <p>Chemical structure of compound 140: A central benzene ring substituted with a 4-iodophenyl group at position 1, a 2-fluoro-4-fluorophenyl group at position 2, and a carbonyl group at position 3. The carbonyl group is connected to a 3-azetidinyl group, which is further connected to a 1-(1-phenylethyl)ethyl group.</p>





Cmpd No.	Structure
141	
142	
143	
144	





Cmpd No.	Structure
145	
146	
147	
148	





Cmpd No.	Structure
149	 <chem>O=C1CN(C1)CNCCc2ccncc2Nc3cc(F)c(I)cc3F</chem>
150	 <chem>O=C1CN(C1)CNCCN(CCNc2ccccc2)Nc3cc(F)c(I)cc3F</chem>
151	 <chem>O=C1CN(C1)CNCCNCCc2ccsc2Nc3cc(F)c(I)cc3F</chem>
152	 <chem>O=C1CN(C1)CNCCNCCN(C(C)C)C(C)CNCc3cc(F)c(I)cc3F</chem>





Cmpd No.	Structure
153	
154	
155	
156	





Cmpd No.	Structure
157	 <chem>CCN1CCN(CC1)CCOC(=O)Nc2cc(F)c(F)cc2Nc3ccc(I)cc3</chem>
158	 <chem>COCCNCC1CCN1C(=O)Nc2cc(F)c(F)cc2Nc3ccc(I)cc3</chem>
159	 <chem>CCOC(=O)N1CCN1C(=O)Nc2cc(F)c(F)cc2Nc3ccc(I)cc3</chem>
160	 <chem>NCC(O)CN1CCN1C(=O)Nc2cc(F)c(F)cc2Nc3ccc(I)cc3</chem>





Cmpd No.	Structure
161	 <chem>COCN1CCOC1C(=O)Nc2cc(F)c(F)cc2Nc3cc(F)c(I)cc3</chem>
162	 <chem>COCN1CCOC1C(=O)Nc2cc(F)c(F)cc2Nc3cc(F)c(I)cc3</chem>
163	 <chem>c1ccoc1CCNCC2OC(C2)C(=O)Nc3cc(F)c(F)cc3Nc4cc(F)c(I)cc4</chem>
164	 <chem>CC(C)(C)NCC2OC(C2)C(=O)Nc3cc(F)c(F)cc3Nc4cc(F)c(I)cc4</chem>





Cmpd No.	Structure
165	
166	
167	
168	





Cmpd No.	Structure
169	
170	
171	
172	





Cmpd No.	Structure
173	
174	
175	
176	





Cmpd No.	Structure
177	
178	
179	
180	





Cmpd No.	Structure
181	 <chem>CC(C)CNC1CCN1C(=O)c2cc(F)c(F)cc2Nc3cc(F)ccc3I</chem>
182	 <chem>CC(C)CCNC1CCN1C(=O)c2cc(F)c(F)cc2Nc3cc(F)ccc3I</chem>
183	 <chem>CCCCNC1CCN1C(=O)c2cc(F)c(F)cc2Nc3cc(F)ccc3I</chem>
184	 <chem>C[C@H](N)C1CCN1C(=O)c2c(F)c3ccncc3cc2Nc4cc(F)ccc4I</chem>





Cmpd No.	Structure
185	
186	
187	
188	





Cmpd No.	Structure
189	
190	
191	
192	






Cmpd No.	Structure
193	
194	
195	
196	






Cmpd No.	Structure
197	
198	
199	
200	






Cmpd No.	Structure
201	
202	
203	
204	






Cmpd No.	Structure
205	
206	
207	
208	






Cmpd No.	Structure
209	
210	
211	
212	







Cmpd No.	Structure
213	
214	
215	
216	
217	






Cmpd No.	Structure
218	 <chem>O=C1N(C1)C(O)CNc2ccc(F)cc2C(=O)Nc3cc(F)c(C(F)(F)F)cc3Nc4ccc(I)cc4</chem>
219	 <chem>O=C1N(C1)C(O)CNc2ccc(F)cc2C(=O)Nc3cc(F)c(C(F)(F)F)cc3Nc4ccc(I)cc4Nc5ncnc6nccn56</chem>
220	 <chem>O=C1N(C1)C(O)CNc2ccc(F)cc2C(=O)Nc3cc(F)c(C(F)(F)F)cc3Nc4ccc(I)cc4Nc5[C@H](O)CCCCC5</chem>
221	 <chem>O=C1N(C1)C(O)CNc2ccc(F)cc2C(=O)Nc3cc(F)c(C(F)(F)F)cc3Nc4ccc(I)cc4Nc5ccccc5</chem>
222	 <chem>CC(=O)Nc1ccc(NC2C(O)C2C(=O)Nc3cc(F)cc(C(F)(F)F)c3Nc4ccc(I)cc4)cc1</chem>






Cmpd No.	Structure
223	
224	
225	
226	
227	






Cmpd No.	Structure
228	
229	
230	
231	
232	

Cmpd No.	Structure
233	
234	
235	
236	
237	






Cmpd No.	Structure
238	
239	
240	
241	
242	
243	







Cmpd No.	Structure
244	 <chem>Oc1cc[nH]c1NC2(CCN2)C(=O)Nc3cc(F)c(F)c(F)c3Nc4ccc(I)cc4</chem>
245	 <chem>OC[C@H](O)[C@H](O)CNc1ccn(c1)C(=O)Nc2cc(F)c(F)c(F)c2Nc3ccc(I)cc3</chem>
246	 <chem>OC1CCCCC1CNc2ccn(c2)C(=O)Nc3cc(F)c(F)c(F)c3Nc4ccc(I)cc4</chem>
247	 <chem>Clc1ccc(NC2(CCN2)C(=O)Nc3cc(F)c(F)c(F)c3Nc4ccc(I)cc4)cc1</chem>
248	 <chem>Clc1ccc(NC2(CCN2)C(=O)Nc3cc(F)c(F)c(F)c3Nc4ccc(I)cc4)cc1</chem>






Cmpd No.	Structure
249	
250	
251	
252	
253	






Cmpd No.	Structure
254	
255	
256	
257	
258	







-75-






Cmpd No.	Structure
259	
260	
261	
262	
263	






Cmpd No.	Structure
264	
265	
266	
267	
268	
269	






Cmpd No.	Structure
270	
271	
272	
273	
274	






Cmpd No.	Structure
275	
276	
277	
278	
279	







Cmpd No.	Structure
280	
281	
282	
283	
284	
285	





Cmpd No.	Structure
286	
287	
288	
289	
290	






Cmpd No.	Structure
291	
292	
293	
294	
295	







Cmpd No.	Structure
296	
297	
298	
299	
300	







Cmpd No.	Structure
301	
302	
303	
304	
305	







Cmpd No.	Structure
306	
307	
308	
309	
310	
311	








Cmpd No.	Structure
312	 <p>and</p>
313	
314	
315	






Cmpd No.	Structure
316	 <p>and</p>
317	
318	
319	
320	







Cmpd No.	Structure
321	
322	
323	
324	
325	
326	







Cmpd No.	Structure
327	
328	
329	
330	
331	
332	

Cmpd No.	Structure
333	
334	
335	
336	
337	
338	

Cmpd No.	Structure
339	
340	
341	
342	
343	
344	
345	

Cmpd No.	Structure
346	
347	
348	
349	
350	

Cmpd No.	Structure
351	
352	
353	
354	
355	
356	

Cmpd No.	Structure
357	
358	
359	
360	
361	
362	

RAS/RAF mutational status in patients with locally advanced or metastatic solid tumors may be determined from tumor tissue samples from patients using methods known in the art, e.g. to ascertain the presence or absence of BRAf (e.g., BRAf^{V600E}), NRas or KRas mutations described above.

- 5 The PI3K inhibitor GDC-0941 and MEK inhibitors including GDC-0973/XL518 of the present invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms.

- 10 The PI3K inhibitor GDC-0941 and MEK inhibitors including GDC-0973/XL518 of the present invention may also exist in different tautomeric forms, and all such forms are embraced within the scope of the invention. The term "tautomer" or "tautomeric form" refers to structural isomers of different energies which are interconvertible via a low energy barrier. For example, proton tautomers (also known as prototropic tautomers) include interconversions via migration of a proton, such as keto-enol and imine-enamine isomerizations. Valence tautomers include inter-
15 conversions by reorganization of some of the bonding electrons.

- The PI3K inhibitor GDC-0941 and MEK inhibitors including GDC-0973/XL518 of the present invention may also be isotopically-labeled, i.e., one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. All isotopes of any particular atom as specified are contemplated within the
20 scope of the compounds of the invention, and their uses. Exemplary isotopes that can be incorporated into the PI3K inhibitor GDC-0941 and MEK inhibitors including GDC-0973/XL518 include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine and iodine, such as ²H, ³H, ¹¹C, ¹³C, ¹⁴C, ¹³N, ¹⁵N, ¹⁵O, ¹⁷O, ¹⁸O, ³²P, ³³P, ³⁵S, ¹⁸F, ³⁶Cl, ¹²³I and ¹²⁵I. Certain isotopically-labeled compounds of the present invention (e.g., those labeled with ³H and
25 ¹⁴C) are useful in compound and/or substrate tissue distribution assays. Tritiated (³H) and carbon-14 (¹⁴C) isotopes are useful for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (²H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Positron emitting isotopes such
30 as ¹⁵O, ¹³N, ¹¹C and ¹⁸F are useful for positron emission tomography (PET) studies to examine substrate receptor occupancy. Isotopically labeled compounds of the present invention can generally be prepared by substituting an isotopically labeled reagent for a non-isotopically

labeled reagent.

The PI3K inhibitor GDC-0941 and MEK inhibitors including GDC-0973/XL518 of the present invention may be administered in the form of a pharmaceutical composition comprising GDC-0941 and a pharmaceutical composition comprising a MEK inhibitor including GDC-

5 0973/XL518, wherein said pharmaceutical compositions comprise one or more pharmaceutically acceptable carrier, glidant, diluent, or excipient.

Suitable carriers, diluents and excipients are well known to those skilled in the art and include materials such as carbohydrates, waxes, water soluble and/or swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water and the like. The particular carrier, diluent
10 or excipient used will depend upon the means and purpose for which the compound of the present invention is being applied. Solvents are generally selected based on solvents recognized by persons skilled in the art as safe (GRAS) to be administered to a mammal. In general, safe solvents are non-toxic aqueous solvents such as water and other non-toxic solvents that are soluble or miscible in water. Suitable aqueous solvents include water, ethanol, propylene glycol, poly-
15 ethylene glycols (e.g., PEG 400, PEG 300), etc. and mixtures thereof. The compositions may also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present inven-
20 tion or pharmaceutical composition thereof) or aid in the manufacturing of the pharmaceutical product (i.e., medicament).

The compositions may be prepared using conventional dissolution and mixing procedures. For example, the bulk drug substance (i.e., compound of the present invention or stabilized form of the compound (e.g., complex with a cyclodextrin derivative or other known complexation agent)
25 is dissolved in a suitable solvent in the presence of one or more of the excipients described above.

The pharmaceutical compositions include those suitable for the administration routes detailed herein. The compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Techniques and formulations
30 generally are found in Remington's Pharmaceutical Sciences 18th Ed. (1995) Mack Publishing Co., Easton, PA. Such methods include the step of bringing into association the active ingredient

with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

Also falling within the scope of this invention are methods of treating a patient with locally advanced or metastatic solid tumors with the combination of the *in vivo* metabolic products of GDC-0941 and MEK inhibitors described herein including GDC-0973/XL-518, in accordance to the regimens described above. Such products may result e.g. from the oxidation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, enzymatic cleavage, and the like, of the administered compound.

10 EXAMPLES

In order to illustrate the invention, the following examples are included. However, it is to be understood that these examples do not limit the invention and are only meant to suggest a method of practicing the invention.

Example 1: In vitro combination efficacy of GDC-0941 and GDC-0973 in a set of melanoma and NSCLC cell lines using a 4-day CellTiterGlo viability assay

Calculusyn, a program utilizing the Chou and Talalay (1984) method of calculating synergy, was used to calculate the combination index and, thus, determine the level of synergy (Figure 1). Strong synergy, as indicated by combination index values ≤ 0.3 , was observed in the majority of melanoma cell lines, about 60% of which carry oncogenic mutations in BRAF. Synergy, as indicated by combination index values ≤ 0.7 , or strong synergy was observed in all but one of the NSCLC cell lines, of which about half carry oncogenic mutations in KRAS.

Example 2: GDC-0973 and GDC-0941 as therapeutic agents in NCI-H2122 (NSCLC, KRAS^{G12C}, PI3K/PTEN WT) and A2058 (Melanoma, BRAF^{V600E}, PTEN^{null}) xenograft models

Both of these models show moderate sensitivity to GDC-0973 or GDC-0941 as single agents; however, neither has exquisite sensitivity to either drug alone, resulting in tumor growth delay, but not stasis or regression. Therefore, pathway activity for both MEK and PI3K is evident in each model, making these relevant models to test combinations of MEK and PI3K inhibitors. NCI-H2122 tumor-bearing animals were treated with GDC-0973 (5 mg/kg, daily), GDC-0941

(50 mg/kg, daily) or the combination. NCI-H2122 tumors showed sensitivity to single agent GDC-0973 with tumor growth inhibition (TGI, relative to vehicle control) of 57% in the 5 mg/kg QD arm (Figure 2). Likewise, NCI-H2122 tumors are also sensitive to single agent GDC-0941 with a TGI of 73% in the 30 mg/kg arm (Figure 2). The combination of GDC-0973 and GDC-0941 resulted in a marked improvement in efficacy over either single agent at both dose levels, resulting in 98% TGI, or tumor stasis (Figure 2). Student's t-tests comparing the moderate doses of GDC-0973 or GDC-0941 to the combination of the two agents revealed that the anti-tumor effect was statistically significant (Student's t-test $p = 0.032$, $p = 0.046$, respectively, on Day 21; Figure 2). GDC-0973 and GDC-0941 were well tolerated when administered alone and in combination, even at higher doses of GDC-0973 at 10 mg/kg, daily with GDC-0941 at 100 mg/kg, daily (data not shown). These data show that GDC-0973 and GDC-0941 have a significant impact on tumor growth in the NCI-H2122 NSCLC xenograft model when used in combination.

Example 3: Moderate and high doses of GDC-0973 (6 and 10 mg/kg, daily) and GDC-0941 (30 and 100 mg/kg, daily) as well as combinations of the lower and higher doses in A2058 tumor-bearing animals

Similar to NCI-H2122, A2058 tumors also show moderate sensitivity to single agent GDC-0973 with TGIs of 41% at 6 mg/kg and 62% at 10 mg/kg (Figure 3A and B, respectively). Likewise, A2058 tumors are also moderately sensitive to single agent GDC-0941 with TGIs of 18% at 30 mg/kg and 56% at 100 mg/kg (Figure 3A and B, respectively). The combination of GDC-0973 and GDC-0941 results in a marked improvement in efficacy over either single agent, resulting in an improvement to 69% TGI at lower doses and 90% TGI at higher doses, approaching tumor stasis (Figure 3A and B, respectively). Student's t-tests comparing the moderate doses of GDC-0973 or GDC-0941 to the combination of the two agents revealed that the anti-tumor effect was statistically significant ($p = 0.048$, $p = 0.008$, respectively, on Day 17). Similarly, comparison of the high doses of GDC-0973 or GDC-0941 to the combination revealed a significant difference (Student's t-test $p = 0.001$, $p = 0.004$, respectively, on Day 17). Combination of GDC-0973 and GDC-0941 did not result in any obvious adverse effects for the mice.

Example 4: Treatment of FaDu (HNSCC) tumor-bearing animals with either single agent GDC-0973 or GDC-0941 or the combination of the two

FaDu tumors show moderate sensitivity to single agent GDC-0973 at 5 mg/kg, daily with a per-

cent tumor growth inhibition (%TGI) of 41% (Fig. 4A). Similarly, FaDu tumors show moderate response to GDC-0941 at 100 mg/kg with a %TGI of 33% (Figure 4A). The combination of GDC-0973 and GDC-0941 at these same doses results in a marked improvement in efficacy over either single agent, resulting in an improvement in %TGI to 96% TGI (Figure 4A). The improved efficacy of the combination was statistically significant versus single agent GDC-0973 and GDC-0941 ($p = 0.0281$ and $p = 0.0034$, respectively, on Day 18).

Example 5: Treatment of SKOV-3 (Ovarian) tumor-bearing animals with either single agent GDC-0973 (10 mg/kg, daily) or GDC-0941 (100 mg/kg, daily) or the combination of the two

SKOV-3 tumors show moderate response to GDC-0941 at 100 mg/kg with a %TGI of 51% (Fig. 4B). The combination of GDC-0973 and GDC-0941 at these same doses results in a marked improvement in efficacy over either single agent, resulting in an improvement in %TGI to 91% TGI (Fig. 4B). The improved efficacy of the combination was statistically significant versus single agent GDC-0973 and GDC-0941 ($p = 0.0017$ and $p = 0.0283$, respectively, on Day 22).

Example 6: Treatment of MOLM-16 (AML) tumor-bearing animals with either single agent GDC-0973 or GDC-0941 or the combination of the two

MOLM-16 tumors show sensitivity to single agent GDC-0973 at 10 mg/kg, daily with a percent tumor growth inhibition (%TGI) of 57% (Fig. 5). Similarly, MOLM-16 tumors show moderate response to GDC-0941 at 100 mg/kg with a %TGI of 40% (Figure 5). The combination of GDC-0973 and GDC-0941 at these same doses results in a marked improvement in efficacy over either single agent, resulting in an improvement in %TGI to 96% TGI (Figure 5). The improved efficacy of the combination was statistically significant versus single agent GDC-0973 and GDC-0941 ($p = 0.0381$ and $p = 0.0158$, respectively, on Day 11).

Example 7: Safety and tolerability study of GDC-0973 and GDC-0941 when administered in combination in patients with locally advanced or metastatic solid tumors

In this study, daily oral dosing of GDC-0973 (5mg or 25mg capsules) and GDC-0941 (15mg or 50mg capsules) administered in combination, daily for 21 days followed by 7 days without study drug, in patients with locally advanced or metastatic solid tumors that are RAS/RAF wild-type, mutant, or unknown. Archival tumor specimens will be obtained from all patients to confirm or

determine BRAF, NRAS or KRAS mutational status and PI3K mutation/PI3K amplification/-PTEN protein status. All patients will have serial FDG-PET imaging as PD biomarker and potential early readout of anti-tumor activity. Treatment will continue for up to 1 year or until disease progression, unacceptable toxicity or any other discontinuation criterion is met. Concurrent GDC-0973 and GDC-0941 administration will be QD (once daily) for 21 consecutive days of a 28-day cycle according to one of the following dosing schema in Figures 6a and 6b. Alternate dosing regimens and schedules may be 14 days on both GDC-0973 and GDC-0941 followed by 14 days off both GDC-0973 and GDC-0941 or intermittent dosing schedules (such as Q2D (every 2 days) and Q4D (every 4 days). Tables 1-A and 1-B show alternative treatment schedule for concurrent oral administration of GDC-0973 and GDC-0941.

Additional patients with RAS/RAF mutant locally advanced or metastatic solid tumors who have had no more than four prior systemic therapies (for their locally advanced or metastatic cancer) will be enrolled to gather additional safety, PK and PD data at one of the treatment schedules in Tables 1-A and 1-B and dosing schema of Figures 6a and 6b. Pre- and post-treatment tumor biopsy samples for PD biomarker analyses will be collected from all patients. All patients will have serial FDG-PET imaging as a potential early readout of anti-tumor activity. Mutational status will be determined retrospectively from mandatory collection of archival tumor tissuesamples.

Table 1-A Treatment Schedule			Table 1-B Treatment Schedule		
Group	GDC-0973	GDC-0941	Group	GDC-0973	GDC-0941
1	20 mg	80 mg			
2	20 mg	100 mg	2a	20 mg	130 mg
3	40 mg	80 mg	3a	60 mg	80 mg
4	40 mg	100 mg			
5	40 mg	130 mg	5a	40 mg	180 mg
6	60 mg	100 mg			
7	60 mg	130 mg	7a	60 mg	180 mg

Disease status will be assessed using Response Evaluation Criteria in Solid Tumors (RECIST) (Therasse et al., New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205–16). Tumor status will be categorized as complete response, partial response, stable disease, or progressive disease per RECIST. Objective response will be confirmed by repeat physical examination or image-based evaluation ≥ 4 weeks after the initial

documentation, per RECIST.




The foregoing description is considered as illustrative only of the principles of the invention.

Further, since numerous modifications and changes will be readily apparent to those skilled in the art, it is not desired to limit the invention to the exact construction and process shown as

5 described above. Accordingly, all suitable modifications and equivalents may be considered to fall within the scope of the present invention.

Claims

1. A method for the treatment of a patient with a locally advanced or metastatic solid tumor comprising administering a therapeutic combination, as a combined formulation or by alternation, to a mammal wherein the therapeutic combination comprises a therapeutically effective amount of
 5 a compound of formula **I** or **II**, or a pharmaceutically acceptable salt of **I** or **II**, and a therapeutically effective amount of a compound of formula **III**, or a pharmaceutically acceptable salt of **III**.




2. The method of claim 1 wherein said therapeutic combination comprises compounds **I** and **III**.
3. The method of claim 1 wherein said therapeutic combination comprises compounds **II** and **III**.
4. The method according to claim 1 wherein said patient is administered concurrently 80 mg, 100 mg, 130 mg or 180 mg of **I** or **II** and 20 mg, 40 mg, or 60 mg of **III**.
5. The method of claim 1 wherein said patient is administered a compound of formula **I** or **II** in combination with a compound of formula **III** wherein said patient is on a 28 day cycle in which
 15 said patient is administered both the compound of formula **I** or **II** and the compound of formula **III** for 21 consecutive days and no compound of formula **I**, **II** or **III** for the next 7 consecutive days.
6. The method of claim 1 wherein said patient is administered a compound of formula **I** or **II** in combination with a compound of formula **III** wherein said patient is on a 28 day cycle in which

said patient is administered both, the compound of formula **I** or **II** and the compound of formula **III** for 14 consecutive days and no compound of formula **I**, **II** or **III** for the next 14 consecutive days.


7. The use of a compound of formula I or II according to claim 1 in combination with a compound of formula III according to claim 1 for the treatment of locally advanced or metastatic solid tumors.
8. The invention as hereinbefore described.

Figure 1
In Vitro Synergy Observed with GDC-0941 and GDC-0973




The combination index (CI) of GDC-0941 and GDC-0973 in a panel of melanoma and NSCLC cell lines was plotted. Each dot represents a single cell line. According to the Chou and Talalay (1984) method, a combination index < 0.3 indicates strong synergy and a combination index < 0.7 indicates synergy.

Figure 2
Combination of GDC-0973 and GDC-0941 in the NCI-H2122
(NSCLC, K-Ras^{G12C}) Mutant Xenograft Model




NCI-H2122 cells (10×10^6 in Hanks Balance Salt Solution (HBSS) + Matrigel) were inoculated into nude mice (nu/nu) and tumors were allowed to establish to an average volume of $\sim 240 \text{ mm}^3$. Treatment was then begun dosing Vehicle (open circles, small dashed lines, $n=10$), GDC-0941 (50 mg/kg, QD, PO; half-filled boxes, dashed lines, $n=5$), GDC-973 (5 mg/kg, QD, PO; filled triangles, large dashed lines, $n=5$), or the combination of GDC-0941 and GDC-0973 (filled diamonds, solid lines, $n=5$). Caliper measurements of animals' tumors and animal weights were taken every 3-4 days throughout the study and tumor volumes were calculated ($TV = [L \times (W^2)]/2$) and plotted \pm SEM. Percent tumor growth inhibition was calculated by calculating the area under the curve (AUC) of each treatment group relative to vehicle control. Student's t-tests were performed on day 21 data to determine significance by p-value.

Figure 3
Combination of GDC-0973 and GDC-0941 in the A2058
(Melanoma, B-Raf^{V600E}, PTEN^{null}) Mutant Xenograft Model




A2058 cells (10×10^6 in Hanks Balance Salt Solution (HBSS) + Matrigel) were inoculated into nude mice (nu/nu) and tumors were allowed to establish to an average volume of $\sim 190 \text{ mm}^3$. (A) Treatment was then begun dosing Vehicle (open circles, small dashed lines, $n=7$), GDC-0941 (30 mg/kg, QD, PO; half-filled boxes, dashed lines, $n=7$), GDC-0973 (6 mg/kg, QD, PO; filled triangles, large dashed lines, $n=7$), or the combination of GDC-0941 and GDC-0973 (filled diamonds, solid lines, $n=7$). (B) Treatment was then begun dosing Vehicle (open circles, small dashed lines, $n=7$), GDC-0941 (100 mg/kg, QD, PO; half-filled boxes, dashed lines, $n=7$), GDC-0973 (10 mg/kg, QD, PO; filled triangles, large dashed lines, $n=7$), or the combination of GDC-0941 and GDC-0973 (filled diamonds, solid lines, $n=7$). Caliper measurements of animals' tumors and animal weights were taken every 3-4 days throughout the study and tumor volumes were calculated ($TV = [L \times (W^2)/2]$) and plotted \pm SEM. Percent tumor growth inhibition was calculated by calculating the area under the curve (AUC) of each treatment group relative to vehicle control. Student's t-tests were performed on day 21 data to determine significance by p-value.

Figure 4



FaDu (A) or SKOV-3 (B) tumor bearing cells were inoculated into nude mice (nu/nu) and tumors were allowed to establish to an average volume of ~190 mm³. (A) Treatment was then begun dosing Vehicle (open circles, small dashed lines, n=7), GDC-0941 (100 mg/kg, QD, PO; filled triangles), GDC-973 (5 mg/kg, QD, PO; filled squares), or the combination of GDC-0941 and GDC-0973 (filled diamonds). (B) Treatment was then begun dosing Vehicle (open circles, small dashed lines, n=7), GDC-0941 (100 mg/kg, QD, PO; filled triangles), GDC-973 (10 mg/kg, QD, PO; filled squares), or the combination of GDC-0941 and GDC-0973 (filled diamonds).

Figure 5



MOLM-16 bearing cells were inoculated into nude mice (nu/nu) and tumors were allowed to establish to an average volume of ~190 mm³. (A) Treatment was then begun dosing Vehicle (open circles), GDC-0941 (100 mg/kg, QD, PO; filled triangles), GDC-973 (10 mg/kg, QD, PO; filled squares), or the combination of GDC-0941 and GDC-0973 (filled diamonds). (B) Treatment was then begun dosing Vehicle (open circles, small dashed lines, n=7), GDC-0941 (100 mg/kg, QD, PO; filled triangles), GDC-973 (5 mg/kg, QD, PO; filled squares), or the combination of GDC-0941 and GDC-973 (filled diamonds).





Figure 6b (Dosing Schema for others)



INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2010/065149

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K31/445 A61K31/5377 A61K35/00
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2007/129161 A2 (PIRAMED LIMITED) 15 November 2007 (2007-11-15) the whole document	1-8
X	WO 2008/070740 A1 (PIRAMED LTD [GB]; GENENTECH INC [US]; BAYLISS TRACY [GB]; CHUCKOWREE I) 12 June 2008 (2008-06-12) page 60	1-8
A	WO 2007/044515 A1 (EXELIXIS INC [US]; AAY NAING [US]; ANAND NEEL KUMAR [US]; BOWLES OWEN) 19 April 2007 (2007-04-19) page 76	1-8

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

23 November 2010

Date of mailing of the international search report

30/11/2010

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Albayrak, Timur

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2010/065149

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2007129161 A2	15-11-2007	AR 060631 A1	02-07-2008
		AT 471940 T	15-07-2010
		AU 2007246793 A1	15-11-2007
		CA 2650303 A1	15-11-2007
		CN 101472930 A	01-07-2009
		DK 2024372 T3	20-09-2010
		EC SP088913 A	30-12-2008
		EP 2246354 A1	03-11-2010
		ES 2347187 T3	26-10-2010
		HK 1127477 A1	22-10-2010
		HR 20100446 T1	30-09-2010
		JP 2009534461 T	24-09-2009
		KR 20090021156 A	27-02-2009
		PT 2024372 E	16-09-2010
		RU 2008145663 A	20-06-2010
		US 2008076768 A1	27-03-2008
		ZA 200809967 A	26-08-2009
WO 2008070740 A1	12-06-2008	AR 064155 A1	18-03-2009
		AU 2007329352 A1	12-06-2008
		CA 2671782 A1	12-06-2008
		CL 35202007 A1	22-08-2008
		EC SP099496 A	29-09-2009
		EP 2114949 A1	11-11-2009
		JP 2010512338 T	22-04-2010
		US 2008242665 A1	02-10-2008
WO 2007044515 A1	19-04-2007	AU 2006302415 A1	19-04-2007
		CA 2622755 A1	19-04-2007
		EA 200801041 A1	27-02-2009
		EP 1934174 A1	25-06-2008
		JP 2009511490 T	19-03-2009
		KR 20080050601 A	09-06-2008
		US 2010249096 A1	30-09-2010
		US 2009156576 A1	18-06-2009